Skip to Content


In the US, Obinutuzumab (obinutuzumab systemic) is a member of the drug class CD20 monoclonal antibodies and is used to treat Chronic Lymphocytic Leukemia and Follicular Lymphoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Anti-CD20 monoclonal antibody

Chemical Name

Immunoglobulin G1, anti-[Homo sapiens CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35)], humanized monoclonal antibody, GA 101; gamma1 heavy chain (1-448)[humanized VH(Homo sapiens FR/Mus muscul (WHO)

Foreign Names

  • Obinutuzumabum (Latin)
  • Obinutuzumab (German)
  • Obinutuzumab (French)
  • Obinutuzumab (Spanish)

Generic Names

  • Obinutuzumab (OS: USAN)
  • Afutuzumab (IS)
  • UNII-O43472U9X8 (IS)

Brand Names

  • Gazyva
    Genentech, United States; Hoffmann-La Roche, Canada; Productos Roche, Chile; Roche, Australia
  • Gazyvaro
    Roche, Germany; Roche, Denmark; Roche, Finland; Roche, Iceland; Roche, Italy; Roche, Poland; Roche, Sweden; Roche, Slovenia; Roche Products, United Kingdom


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.